Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Gain Therapeutics, Inc. Gain Therapeutics to Hold a Business Update Conference Call on July 1, 2024 June 28, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO June 27, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Presents GT-02287 Data at Federation of European Neuroscience Societies (FENS) Forum 2024 Demonstrating Improvements in Cognitive Performance in a Preclinical Model of GBA1 Parkinson’s disease June 27, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics to Participate at H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference June 25, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Pricing of $11.0 Million Public Offering June 13, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Proposed Public Offering June 13, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Poster Presentation at Federation of European Neuroscience Societies (FENS) Forum 2024 May 30, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update May 14, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease April 24, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer April 08, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Strengthens Management Team and Appoints Jonas Hannestad, M.D., Ph.D. as Chief Medical Officer April 01, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update March 26, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics to Present at Public Ventures Discovery Day March 15, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Presents Data at the AD/PD™ 2024 Conference Demonstrating the Mechanism of Action of GT-02287, its Clinical Stage GCase Regulator for the Treatment of Parkinson’s Disease March 05, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces the Initiation of the Multiple Ascending Dose (MAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease February 27, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight February 14, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX UPDATE - Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease February 06, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics’ GT-02287 Completely Restores Motor Function in Mouse Models of Parkinson’s Disease February 06, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics’ CEO Matthias Alder Issues Letter to Shareholders and Provides Operational Update January 31, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Acceptance of Late-Breaking Abstract for Platform Presentation at the 20th Annual WORLDSymposium™ 2024 January 02, 2024 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics to Participate in FORCE Family Office Event with Zacks Small-Cap Research December 04, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model December 01, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics to Participate in AI Driven Drug Discovery Summit November 29, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Closing of $10.1 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants, Including Full Exercise of Over-Allotment Option November 24, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Pricing of $9.4 Million Public Offering and Concurrent Private Placement of Common Stock and Warrants November 21, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Proposed Public Offering November 20, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update November 14, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics Announces Dosing of First Two Subjects in Phase 1 Clinical Trial of GT-02287, a Novel GCase-targeting Small Molecule Therapy for GBA1 Parkinson’s Disease October 04, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics to Participate at Cantor Fitzgerald Global Healthcare Conference 2023 September 25, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Gain Therapeutics to Present at the Cambridge Healthtech Institute’s 2nd Annual Neurodegeneration Targets Conference September 20, 2023 From Gain Therapeutics, Inc. Via GlobeNewswire Tickers GANX Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.